Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $33.02 USD
Change Today +0.19 / 0.58%
Volume 26.0K
As of 11:46 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Adam R. Havey

Executive Vice President and President of Biodefense Division, Emergent BioSolutions, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

As of Fiscal Year 2014


Mr. Adam R. Havey has been the President of Biodefense Division and Executive Vice President of Emergent BioSolutions, Inc. since March 2011. Mr. Havey served as an Executive Vice President of BioDefense Division of Emergent BioSolutions, Inc. since March 2011. He served as the President of Emergent BioDefense Operations Lansing LLC from January 2009 to February 2011 and Vice President of Business Operations from November 2007 to December 2008, Senior Director of Manufacturing ...

Read Full Background

Corporate Headquarters*

400 Professional Drive
Gaithersburg, Maryland 20879

United States

Phone: 240-631-3200
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.


Bachelor's Degree
Michigan State University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$558,672

Stock Options*

Restricted Stock Awards$394,945
All Other Compensation$7,800
Exercised Options23,382
Exercised Options Value$230,947
Exercisable Options46,931
Exercisable Options Value$342,977
Unexercisable Options48,925
Unexercisable Options Value$255,654
Total Value of Options$829,578
Total Number of Options119,238

Total Compensation*

Total Annual Cash Compensation$566,472
Total Short Term Compensation$558,672
Other Long Term Compensation$402,745
Total Calculated Compensation$1,241,984
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $33.02 USD +0.19


Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
William S. Marth Chief Executive Officer, President and Director
Albany Molecular Research Inc.
Peter William Grant Chief Executive Officer and Executive Director
Skyepharma PLC
567.0K GBP
Paul Chaplin MSc, Ph.D.Chief Executive Officer and President
Bavarian Nordic A/S
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at